Kornimate/medical-research-clean huggingface dataset:
the standard of care combined with glucocorticoid in elderly people with mild or moderate covid-19

Conditions: COVID-19

Summary: this study is aimed to explore the dual-dimensional early intervention strategy of standard of care combined with host immunomodulation in elderly patients with mild and moderate covid-19.

in this multicentre, randomized, controlled, and adaptive platform trial exploring the efficacy and safety of short-term and low-dose glucocorticoid combined with standard of care in mild or moderate elderly patients (with or without other high-risk factors) who are over 65 years.we are looking for the best treatment strategy to prevent mild or moderate covid-19 from developing into severe/critical covid-19, so as to reduce the risk of disease progression and death in the elderly patients and benefit more patients.

Eligibility criteria:
inclusion criteria: * age ≥ 65; * male or female; * positive test for coronavirus antigen or nucleic acid； * within 7 days of onset (fever and/or cough) ； * mild and moderate；mild: respiratory tract infection is the main manifestation, such as dry throat, sore throat, cough, fever；moderate: continuous high fever\>3 days or (and) cough, shortness of breath, etc., but respiratory rate (rr)\ 93% when breathing air at rest. imaging findings of characteristic pneumonia caused by covid-19 infection； * the patient is willing to participate in the trial treatment and follow-up, and sign the informed consent form (if the patient lacks the ability to give informed consent due to his serious medical condition, such as acute respiratory failure or the need for respiratory support, he can obtain the consent of the patient's legal representative)； * no systemic glucocorticoids treatment in the past 7 days； exclusion criteria: * serious and uncontrolled comorbidities； * expected lifetime is less than 1 month； * severe/critical; * other situations that are evaluated by researchers as not suitable for participating the study. criteria for discontinuation * the subject could not benefit after treatment (discontinued patients could be analyzed according to the pp analysis set); withdrawal criteria (if any of the following items are required) * the subject asked to withdraw from the study; * the subject needs to withdraw from the study after clinical observation after discontinuing treatment; * the subject died or lost to follow-up.

Keywords: glucocorticoids standard of care mild and moderate covid-19
safety and efficacy study of cp-675,206 in hiv-infected patients

Conditions: Human Immunodeficiency Virus

Summary: the purpose of this study is to determine if cp-675,206, a monoclonal antibody to ctla4, is safe and well-tolerated, reduces viral load, and improves immune function in patients infected with hiv.


Eligibility criteria:
inclusion criteria: * hiv infected man or woman at least 18 years of age who is available for a follow up period of at least 3 months * has been on a stable antiretroviral regimen for ≥3 months and willing to remain on current antiretroviral regimen for an additional 3 months or has been off of antiretroviral therapy for at least 8 weeks and willing to remain off of antiretroviral therapy for another 3 months * plasma hiv 1 rna ≥5,000 copies/ml measured by roche amplicor hiv 1 monitor at the screening visit * cd4 t-cells ≥200 cells/mm3 exclusion criteria: * history of, or significant evidence of risk for, chronic inflammatory or autoimmunedisease (eg, addison's disease, asthma, celiac disease, multiple sclerosis, graves disease, hashimoto's thyroiditis, inflammatory bowel disease, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, etc) * history of inflammatory bowel disease (eg, crohn's disease or ulcerative colitis), celiac disease, or other chronic gastrointestinal conditions associated with diarrhea, or current acute colitis of any origin, and any history of diverticulitis (even a single episode) or evidence of diverticulitis at baseline, including evidence limited to ct-scan only * exposure within the previous 3 months to a drug known to have immunomodulatory effects (eg, il 2)

Keywords: hiv therapeutic vaccine
motor network physiology

Conditions: Parkinson Disease; Essential Tremor

Summary: the brain networks controlling movement are complex, involving multiple areas of the brain. some neurological disorders, like parkinson's disease (pd) and essential tremor (et), cause abnormalities in these brain networks. deep brain stimulation is a treatment that is used to treat these types of neurological diseases and is thought to help patients by modulating brain networks responsible for movement. levodopa medication is also used to modulate this brain networks in patients with pd. the overall objective is to develop a unified theory of basal ganglia thalamocortical (bgtc) circuit dynamics that accounts for disease symptomatology, movement, and their inter-relationship. the underlying hypothesis, is that the rigidity and bradykinesia of pd are fundamentally related to excessive functional coupling across nodes in the bgtc motor circuit impeding effective information flow. in this research, the investigator will take advantage of the unique opportunity provided by awake deep brain stimulation surgery to learn more about how the brain functions in a diseased state and how deep brain stimulation changes these networks to make movement more normal. the investigator will simultaneously assess cortical and subcortical electrophysiology in relation to clinical symptoms and behavioral measures and in response to deep brain stimulation, cortical stimulation, and pharmacologic therapy in patients undergoing deep brain stimulation (dbs) implantation surgery.


Eligibility criteria:
inclusion criteria: * diagnosis of parkinson's disease who have been recommended to undergo deep brain stimulation for management of their movement disorder * preoperative mri without evidence of cortical or subdural adhesions or vascular abnormalities * willingness and ability to cooperate during conscious operative procedure for up to 40 minutes exclusion criteria: * patients with recent use (within one week) of anticoagulant or antiplatelet agents * neurocognitive testing indicating amnestic cognitive deficits

Keywords: deep brain stimulation levodopa medication motor cortex basal ganglia thalamus
the influence of fluid removal using continuous venovenous hemofiltration (cvvh) on intra-abdominal pressure and kidney function

Conditions: Critically Ill; Intra-Abdominal Hypertension; Abdominal Compartment Syndrome; Acute Kidney Injury

Summary: intra- abdominal hypertension (iah) and abdominal compartment syndrome (acs) are a cause of organ dysfunction in critically ill patients. iah develops due to abdominal lesions (primary iah) or extra-abdominal processes (secondary iah). secondary iah arises due to decreased abdominal wall compliance and gut edema caused by capillary leak and excessive fluid resuscitation. decreasing intra-abdominal pressure (iap) using decompressieve laparotomy has been shown to improve organ dysfunction. however, laparotomy is generally avoided in patients with secondary iah due to the risk of abdominal complications. acute kidney injury (aki) is one of the first and most pronounced organ failures associated with iah and many patients with aki in the icu require renal replacement therapy (rrt). fluid removal using continuous rrt (crrt) has been demonstrated to decrease iap in small series and selected patients. the aim of this study is to evaluate whether fluid removal using cvvh in patients with iah, fluid overload and aki is feasible and whether it has a beneficial effect on organ dysfunction (compared to cvvh without net fluid removal).


Eligibility criteria:
inclusion criteria: * adult patients (\>18y old) of either gender * admitted to the icu * sedated and mechanically ventilated (and expected to remain so for at least 48h) * informed consent given * admitted to the icu for \<7 days or during the first 7 days of a new shock episode * aki requiring rrt according to treating physician * iap \>12mmhg being attributed to fluid overload by treating physician exclusion criteria: * included in the same study before * vasopressor and/or inotrope dose needed above noradrenaline 1µg/kg/min and dobutamine 10µg/kg/min * pao2/fio2 ratio \<100

Keywords: critically ill patients with positive fluid balance, iah and aki requiring rrt
endoscopic ultrasound-guided drainage of walled off necrosis (won)

Conditions: Pancreatic Pseudocyst

Summary: the purpose of this study is to compare the effect of lumen-apposing metal stent (lams) and double pigtail plastic stents (dppss) on the drainage of pancreatic walled-off necrosis (won), mainly to observe the efficacy and safety of lams for won.

patient with pancreatic walled-off necrosis (won) would be treated randomized with lumen-apposing metal stent (lams) or double pigtail plastic stents (dppss) under the guidance of endoscopic ultrasonography. the investigators compare the effect of the two stents, including technical success, clinical success, adverse event, recurrence, and so on.

Eligibility criteria:
inclusion criteria: 1. subject with ages from 18-80 years old 2. subject with pancreatic pseudocysts confirmed by ct 3. subject with a history of msap or sap, the pseudocysts were formed more than 3 months 4. the size of pseudocyst is more than 6 cm, and the cyst adjacent to the gastric wall 5. subject has the symptoms related with the pseudocyst 6. the consent form has been signed exclusion criteria: 1. subject is younger than 18 years or older than 80 years 2. pancreatic pseudocyst communicate with the main pancreatic duct 3. subject can't accept the endoscopic procedure 4. pancreatic pseudocyst with infection or subject diagnosed with pancreatic abscess 5. the distance between gastric and the wall of the pseudocyst is more than 1 cm 6. subject with 2 or more than 2 cysts 7. subject has blood coagulation dysfunction 8. pregnant or subject has mental disorders
lung open ventilation to decrease mortality in the acute respiratory distress syndrome

Conditions: Acute Respiratory Distress Syndrome

Summary: a multinational, randomized trial comparing two lung protecting strategies of respiratory life support among critically ill patients with severe lung injury.

to compare an innovative lung open ventilation strategy with a proven low tidal volume strategy, hypothesizing that the lung open ventilation strategy may reduce mortality, other organ dysfunction, and the duration of mechanical ventilation, intensive care, and hospital stay.

Eligibility criteria:
inclusion criteria: * invasive mechanical ventilation * acute respiratory insufficiency (within past 28 days) * bilateral infiltrates on frontal chest radiograph * hypoxemia, defined as pao2/fio2\<=250 exclusion criteria: * primary cause of respiratory failure is cardiac * anticipated duration of mechanical ventilation \< 48 hours * inability to wean other experimental ventilation strategies * severe chronic respiratory disease * neuromuscular disease that will prolong mechanical ventilation * conditions where hypercapnia-induced intracranial hypertension should be avoided * morbid obesity (\> 1kg per cm body weight) * pregnancy * very unlikely to survive and lack of commitment to life support underlying irreversible condition with 6 month mortality \>= 50% * greater than 48 hours elapsed since first eligible * current participation in competing trial * lack of physician, patient or proxy consent
the effect of relaxation and stretching exercises on pain and quality of life in women with primary dysmenorrhea

Conditions: Primary Dysmenorrhea

Summary: the study aimed to examine the effect of stretching and relaxation exercises on pain and quality of life in women with primary dysmenorrhea.

while dysmenorrhea is a frequent gynecologic condition that affects women of reproductive age, young women are generally unaware of it. dysmenorrhea is divided into two main types based on its pathophysiology: * primary dysmenorrhea (pd), is menstrual discomfort coupled with regular ovulatory cycles and a defined physiological explanation. adolescents and young adults are the most affected. * secondary dysmenorrhea (sd), is defined as menstruation discomfort caused by a disease (endometriosis, fibroids, adenomyosis, pelvic adhesions, endometrial polyps, pelvic inflammatory disease) or the use of an intrauterine contraceptive device. dysmenorrhea is a type of persistent, cyclic pelvic pain that can be accompanied by nausea, vomiting, diarrhea, headache, exhaustion, back pain, and dizziness. in studies conducted on university students in turkey in 2009 and 2010, 87.7% and 72.7% (respectively) of the students reported that they had pain during the menstrual period. the release of prostaglandins into the uterine tissue is assumed to be the cause of dysmenorrhea. as a result, nonsteroidal anti-inflammatory drugs (nsaids) are the usual first-line treatment for dysmenorrhea. oral contraceptives, acupuncture, acupressure, yoga, and vitamin b1 are among the additional treatments that have been suggested. it has been suggested that exercise can help with dysmenorrhea. physical exercise has been suggested as a medical treatment for the treatment of dysmenorrhea and related symptoms by several writers. billig was one of the first to advocate for exercise as a treatment for dysmenorrhea; he devised a set of stretching exercises and found a reduction in dysmenorrheic symptoms. h1: there is a significant difference in pain and quality of life in the group with stretching and relaxation exercises compared to the group with stretching exercises.

Eligibility criteria:
inclusion criteria: * participants in the study voluntarily. * participants in ages between 18-25 years of age. * participants have a sedentary lifestyle. * participant's pain intensity of more than 40 mm during the menstrual period according to the vas. exclusion criteria: * using regular drugs like nsaids * presence of sd * having an irregular menstrual cycle * presence of chronic disease.

Keywords: primary dysmenorrhea pain exercise stretching
a pharmacodynamics, safety, and pharmacokinetics study of thn201 versus donepezil in healthy male volunteers

Conditions: Cognitive Impairment; Alzheimer Disease

Summary: this study explores the safety, pharmacodynamics and pharmacokinetics of thn201 a combination of donepezil and mefloquine to improve cognitive function in healthy male volunteers after impairment by a scopolamine challenge.

this is a double-blind, 3-arm, parallel group study of 15 days duration including a scopolamine challenge at d15. healthy male subjects will receive daily doses of thn201 (donepezil 5 mg and mefloquine), donepezil 5 mg or placebo and one subcutaneous injection of scopolamine 0.5 mg on d15. cognitive function, eeg and p300 will be assessed at baseline and before and after scopolamine challenge at d15. a final safety evaluation will be performed 2 weeks after the end of the treatment period. pharmacokinetic assessments will be performed to obtain a time/concentration profile of donepezil and mefloquine.

Eligibility criteria:
inclusion criteria: * a body mass index (bmi), calculated as weight in kg/(height in m)², from 18 to 30 kg/m², inclusive * healthy as determined by the investigator after a comprehensive clinical assessment based on medical history, physical examination, clinical laboratory test results, vital sign measurements, blood pressure (bp), heart rate (hr) and digital 12-lead ecg readings (all results should be normal or, if out of range, they should be non-clinically significant as determined by the investigator) exclusion criteria: * any significant cardiovascular (e.g. heart failure), pulmonary (including asthma), hepatic, renal, respiratory (e.g. asthma), gastrointestinal, endocrine (e.g. diabetes, dyslipidaemia), immunologic, dermatological, haematological, neurologic, psychiatric disease, history of any clinically important drug allergy, systemic or presence of infectious disease. * current suicide risk or history of suicide risk (c-ssrs baseline: "yes" answer to items 4 and/or 5). * brain imaging (mri) at screening showing anatomical or vascular abnormality of any type. * eeg examination at screening showing abnormal (epileptiform) activities. * symptomatic hypotension, * participants with, or with a history of cardiac arrhythmia or cardiac disease or a personal or family history of long qt syndrome or a family history of sudden death. * presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician. * antimalarial medicine intake or returning from a malaria-endemic area within the 12 last months before the first imp administration. * planning to visit a country requiring antimalarial chemoprophylaxis during the study period. * history of adverse reaction after a previous mefloquine intake. * contraindication for the use of aricept® or for one of its excipients. * contraindication for the use of piperidine derivative compounds or for other cholinesterase inhibitors. * contraindication for the use of lariam® or for one of its excipients. * contraindication for the use of scopolamine s.c. injection. * history or presence of drug or alcohol abuse (alcohol consumption \> 21 units / week).
impact of stent length on short term outcomes in patients with stable coronary disease undergoing pci

Conditions: Stable Chronic Angina

Summary: impact of stent length on short term outcomes in patients with stable coronary artery disease undergoing pci

impact of stent length on short term outcomes in patients with stable coronary artery disease undergoing pci. the investigators will follow up patient clinically and use lab investigation.

Eligibility criteria:
inclusion criteria: * patient was cad referred for elective pc as single vessel exclusion criteria: * patients admitted acs patients with primary pci ptca without stenting no complete revascularization pci-related coronary complication (diessaction,no really)
midodrine and albumin for cirrhotic patients with functional renal impairment

Conditions: Cirrhosis; Renal Failure

Summary: the objective of the study was evaluate the effect of administration of midodrine and albumin on renal function in patients with cirrhosis and creatinine greater than 1,2mg/dl.

twenty patients with cirrhosis and functional renal impairment, defined by a serum creatinine greater than 1,2mg/dl, will be included. patients will receive daily midodrine at a dose of 10mg tid and 40g of albumin at 15-day interval. the follow-up period will be of 12 weeks. in all patients, liver and renal function, and vasoactive hormones (plasma renin activity, aldosterone, noradrenaline, adh, endothelin and anf)will be determined at baseline conditions. at this moment, glomerular filtration rate and renal plasma flow determined by isotopic techniques as ambulatory blood pressure monitoring through a 24-hour period will be performed too. all these determinations will be repeated at 4 and 12 weeks. during the study period, just before the albumin infusions, blood will be drawn for creatinine and electrolytes determinations and these will be recorded as well physical examination performed.

Eligibility criteria:
inclusion criteria: * liver cirrhosis * serum creatinine greater than 1,2 mg/dl * to have given written informed consent exclusion criteria: * pregnancy * systolic blood pressure above 150mmhg and/or diastolic blood pressure above 90mmhg * previous treatment with transjugular intrahepatic portosystemic shunt (tips) or surgical shunts * antibiotic treatment in the previous 7 days before inclusion, except for prophylaxis of spontaneous bacterial peritonitis * infection by hiv * contraindications for albumin and/or midodrine use

Keywords: cirrhosis renal failure hepatorenal syndrome albumine midodrine
the effect of remifentanil-dexmedetomidine compared with remifentanil-midazolam on patient's satisfaction

Conditions: Peripheral Arterial Occlusive Disease

Summary: percutaneous trans-arterial angioplasty(pta) is one of the peripheral arterial occlusive disease(paod) treatment. during and after pta, ischemia-reperfusion pain is induced so proper analgesia is important. ischemia-reperfusion injury is due to reactive oxygen species. dexmedetomidine has analgesic, sedative and anti oxidant effect. so the investigators research the patient's satisfaction that are given the dexmedetomidine during pta procedure.


Eligibility criteria:
inclusion criteria: * patients who are scheduled to undergo percutaneous trans-arterial angioplasty * american society of anesthesiologists (asa) class i, ii, iii exclusion criteria: subjects are ineligible if they have the below condition * psychiatric medication * myocardial infarction within 1 year * cardiac surgery within 1 year * heart failure * fever (\>38 degree) * uncontrolled hypertension * cognitive dysfunction * disabling mental change disorder * being unable to communicate or speak korean
hfno reducing the incidence of hypoxia for hysteroscopy sedated with propofol

Conditions: Endometritis; Tuberculous Endometritis; Subseptate Uterus; Endometrial Polyps

Summary: to determine whether high-flow nasal cannula oxygen can reduce the incidence of hypoxia during the procedure of sedated hysteroscopy.


Eligibility criteria:
inclusion criteria: 1. 20 years old ≤ age ≤ 50 years old, female. 2. undergoing hysteroscopy sedated with propofol for diagnosis or treatment. 3. informed consent 4. bmi≤28kg/m2. 5. asa physical status ⅰ\~ ⅱ. exclusion criteria: 1. epistaxis, nasal congestion and nasal mucosal damage. 2. confirmed brain disease (cranial trauma, tumor, stroke, cognitive dysfunction etc.). 3. confirmed severe heart disease (heart failure, angina pectoris, myocardial infarction, arrhythmia, etc.). 4. confirmed severe lung diseases (upper respiratory tract infection, asthma, bronchitis, copd, bullae, pulmonary embolism, pulmonary edema, lung cancer, etc.). 5. pregnant women. 6. acute and chronic hepatitis or liver cirrhosis with severe abnormal liver function. 7. acute and chronic nephritis with severe abnormal renal function or renal failure. 8. needing oxygen inhalation for underlying diseases. 9. emergency surgery. 10. combined with multiple trauma. 11. allergic to soybean

Keywords: hfno hysteroscopy sedation hypoxia
proprioceptive training and low back pain

Conditions: Proprioceptive Training; Low Back Pain

Summary: proprioceptive weighting changes may explain differences in postural control performance. deficits in proprioception are found in a subgroup of patients with low back pain. the aim of the study is to clarify whether proprioceptive training has a positive effect on proprioceptive postural control in individuals with recurrent low back pain.


Eligibility criteria:
inclusion criteria individuals with low back pain: * age: 18-45 years old * at least 1 year of low back pain with/without referred pain in buttock/thigh * at least 3 episodes of disabling low back pain * at least a score of 20% on the oswestry disability index * willingness to sign the informed consent exclusion criteria: * history of major trauma and/or major orthopedic surgery of the spine, the pelvis or the lower quadrant * one of the following conditions: parkinson, multiple sclerosis, stroke, history of vestibular disorder, respiratory disease, pregnancy * radicular symptoms * not dutch-speaking * strong opioids * neck pain * smoking history